Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (1): 75-80.doi: 10.6040/j.issn.1671-7554.0.2018.075

Previous Articles    

Efficacy and safety of direct-acting antiviral therapy for hepatitis C after renal transplantation

MAO Yijie, ZHANG Xufeng, LIU Shuangde, LIU Xiaoli, YAN Jieke, XU Dongsheng, PAN Wengu, TIAN Chuan   

  1. Department of Kidney Transplantation, Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Published:2022-09-27

PDF (PC)

8

Abstract: Objective To assess the efficacy and safety of direct-acting antiviral(DAA)therapy for hepatitis C after renal transplantation. Methods By a retrospective analysis, we recruited seven patients who were infected with hepatitis C virus(HCV RNA)and treated with direct-acting antiviral agents therapy after kidney transplantation in our transplantation department. Serum HCV RNA, alanine transaminase(ALT), estimate glomerular filtration rate(eGFR)and serum creatinine level were measured at baseline, 2nd, 4th, 12th week of treatment, and 12th, 24th, 48th week after the treatment. Survival rate of these patients at 1 year post-therapy was analyzed. Results Seven kidney graft recipients infected with HCV were enrolled in our study. All these patients were given DAA therapy for 12 weeks. At the end of therapy, HCV RNA was negative in all patients. The serological test had a rapid virologic response(RVR)of 100%(7/7), SVR12, SVR24 were 100%, and ALT at 2th week of treatment had improvement compared with that before treatment. ALT levels remained stable thereafter; eGFR and blood muscle levels remained stable throughout the study period. Conclusion During the 1 year follow-up period, the therapy for patients infected with hepatitis C virus after kidney transplantation is safe and effective, and kidney function after transplantation was relatively stable during the research period.

Key words: Kidney transplantation, Chronic hepatitis, Direct-acting antiviral agents, Virologic response

CLC Number: 

  • R692
[1] Poveda E, Wyles DL, Mena A, et al. Update on hepatitis C virus resistance to direct-acting antiviral agents[J]. Antiviral Res, 2014, 108(4): 181-191.
[2] Ju W, Yang S, Feng S, et al. Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6[J]. Virol J, 2015, 12(1): 1-6.
[3] 聂红明, 陈建杰, 汪蓉,等. 中国汉族人群慢性丙型肝炎病毒基因型分布规律研究[J]. 中华流行病学杂志,2012, 33(5): 501-504. NIE Hongming, CHEN Jianjie, WANG Rong, et al. Genotypes distribution of hepatitis C virus through multi-center, large sample studies among chronic hepatitis C patients in Chinese Han population[J]. Chinese Journal of Epidemiology, 2012, 33(5): 501-504.
[4] Ghaderi Zefrehi H, Gholami Fesharaki M,et al. The distribution of hepatitis C virus genotypes in middle eastern countries: a systematic review and meta-analysis[J]. Hepat Mon, 2016, 16(9): e40357. doi: 10.5812/hepatmon.40357.
[5] Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing[J]. HepatolInt, 2016, 10(5): 681-701.
[6] Scott N, McBryde E, Vickerman P, et al. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral therapys[J]. BMC Med, 2015, 13: 198. doi: 10.1186/s12916-015-0440-2.
[7] Bunchorntavakul C, Maneerattanaporn M, Chavalitdhamrong D. Management of patients with hepatitis C infection and renal disease[J]. World J Hepatol, 2015, 7(2): 213-225.
[8] Signorovitch JE, Betts KA, Song Y, et al. Comparative efficacy and safety of daclatasvir/asunaprevirversus IFN-based regimens in genotype 1b hepatitis C virus infection[J]. J Comp Eff Res, 2015, 4(6): 593-605.
[9] Hundemer GL, Sise ME, Wisocky J, et al. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency[J]. Infect Dis(Lond), 2015, 47(12): 924-929.
[10] Kamar N, Marion O, Rostaing L, et al. Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation[J]. Am J Transplant, 2016, 16(5): 1474-1479.
[11] 魏来, 侯金林, 陈红松, 等. 丙型肝炎防治指南(2015年更新版)[J].中华肝脏病杂志, 2015,23(12): 906-923. WEI Lai, HOU Jinlin, CHEN Hongsong, et al. The guideline of prevention and treatment for hepatitis C: a 2015 update[J]. Chinese journal of hepatology, 2015, 23(12): 906-923.
[12] Gentil GMA, Esforzado N, Cruzado JM, et al. Harmful effects of viral replication in sero-positive hepatitis C virus renal transplant recipients[J]. Transplantation, 2012, 94(11): 1131-1137.
[13] 张萍, 段志强, 杨丽南,等. 丙肝病毒感染的肾移植受者的临床观察[J]. 西南国防医药, 2015, 25(4): 377-380.
[14] Cai Q, Zhang X, Lin C, et al. 24 versus 48 weeks of peginterferon plus ribavirin in hepatitis C virus genotype 6 chronically infected patients with a rapid virological response: anon-inferiority randomized controlled trial[J]. PLoS One, 2015, 10(10): e0140853.doi: 10.1371/journal.pone.0140853
[15] Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C[J]. Gut, 2007, 56(4): 553-559.
[16] Ge YZ, Wu R, Jia RP, et al. Association between interferon gamma +874 T>A polymorphism and acute renal allograft rejection: evidence from published studies[J]. MolBiol Rep, 2013, 40(10): 6043-6051.
[17] Brown RS, O'Leary JG, Reddy KR, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network[J]. Liver Transpl, 2016, 22(1): 24-33.
[18] Hézode C, Lebray P, De Ledinghen V, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme[J]. Liver Int, 2017, 37(9): 1314-1324.
[19] Hussein NR, Saleem ZS. Successful treatment of hepatitis C virus genotype 4 in renal transplant recipients with direct-acting antiviral agents[J]. Am J Transplant, 2016, 16(7): 2237-2238.
[20] Sawinski D, Kaur N, Ajeti A, et al. Successful treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents[J]. Am J Transplant, 2016, 16(5): 1588-1595.
[21] Tabernilla A, Grandal M, Pernas B, et al. Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing therapy duration[J]. Eur J Gastroenterol Hepatol, 2017, 29(7): 781-785.
[22] Rostaing L, Alric L, Kamar N. Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients[J]. TransplInt, 2016, 29(12): 1257-1265.
[23] Lin MV, Sise ME, Pavlakis M, et al. Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection[J]. PLoS One, 2016, 11(7): e0158431. doi: 10.1371/journal.pone.0158431.
[24] Kamar N, Marion O, Rostaing L, et al. Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection afterkidney transplantation[J]. Am J Transplant, 2016, 16(5): 1474-1479.
[25] 牛英,明英姿,佘兴国,等. 直接抗病毒药物治疗肾移植术后丙型病毒性肝炎疗效与安全性的临床观察[J]. 器官移植, 2017, 1(8): 49-53. NIU Ying, MING Yingzi, SHE Xingguo, et al. Preliminary observation of clinical efficacy and safety of direct-acting antiviral agents for hepatitis C virus following renal transplantation[J]. Organ Transplantation, 2017, 1(8): 49-53.
[26] Beinhardt S, Al Zoairy R, Ferenci P, et al. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and post-kidney transplantation setting[J]. Transpl Int, 2016, 29(9): 999-1007.
[1] SHENG Xuan, WANG Yonge, GUO Dan, LAN Meng, FAN Fengjing, DING Hongyu. Effects of body mass index and renal subcutaneous depth on the results of virtual touch tissue imaging quantification in renal transplant patients [J]. Journal of Shandong University (Health Sciences), 2018, 56(12): 68-72.
[2] LIU Qiuxia, WANG Lei, LIU Feng, QU Yundong, YE Qian, QIAN Yu, ZHANG Yuan, ZHANG Lixin. Hypophosphatemia during long-term adefovir dipivoxil therapy in patients with hepatitis B virus infection [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 73-78.
[3] ZHANG Kun, ZHAGN Xiaoguo, CUI Xingxing, CHEN Shijun. Expression of apoptosis-related genes in peripheral blood mononuclear cells of patients with HBV infection and the relationship with chronicity of hepatitis B [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(7): 38-42.
[4] QIAN Yu, QU Yundong, WANG Ziyu, LIU Feng, YE Qian, WANG Lei. Risk factors to influence renal function of patients with chronic hepatitis B virus infection [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(1): 29-32.
[5] LIU Tongyan1, ZHANG Longyue2, LI Yuerong3, SUN Jingli2, HAN Zenglu3, LI Zhiquan1, ZHANG Lixin1, WANG Lei1. Prospective cohort observation of patients with hepatitis B e antigen-positive chronic hepatitis B treated by Adefovir dipivoxil and Interferon-α [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(6): 72-78.
[6] PAN Jiachao1,2, ZHANG Le1,2, XU Linlin3, SHAN Xiaoyu2, DU Wenjun2, CHEN Shijun2. Role of innate immunity induced by AIM2 in the pathogenesis of chronic hepatitis B [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(4): 74-79.
[7] LIU Wei1, DING Ai-kun2, LI Cheng2, SHAN Rong3, WANG Chang-yuan1,2. Significance and influential factors of Fibroscan detection  in the progress of patients with chronic hepatitis B disease [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(1): 85-88.
[8] LIU Yan, LIU Cong-cong, SHI Dan-dan, SUN Xiao, LI Jie. Value of virtual touch tissue quantification in the diagnosis of chronic allograft nephropathy after renal transplantation [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(8): 78-81.
[9] FU Xiao-li， WANG Lei， LIU Feng. HBsAg quantitative value in different stages of hepatitis B virus infection and its correlations with serum HBV DNA and age [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(5): 94-98.
[10] ZHANG Xiu-zhen, LIU Li, LIU Qian. Relativity of serum leptin level and response to antiviral
therapy in patients with chronic hepatitis B [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(9): 96-99.
[11] HAN Xue, WANG Qing, CUI Fengyu. Application of multislice CT angiography  in living renal donors before nephrectomy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(4): 102-105.
[12] ZHANG Xiao-guo,WANG Min,CHEN Jian. Relationship between hepatitis C virus quasi-species complexity and its response to interferon therapy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(2): 171-173.
[13] LI Xiao-ying,WANG Lei,LIU Feng. Durability of the effects after cessation of lamivudine for 47 patients with HBeAg-negative chronic hepatitis B [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(9): 938-939.
[14] ZHAO Jing-jie,LIU Jun-li,TIAN Chuan,ZHANG Cai. Effect of vitamin B on hyperhomocysteinemia in renal-transplant recipients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(8): 771-773.
[15] WANG Hong-wei,LIU Shuang-de,YAN Jie-ke,TIAN Chuan,XU Dong-sheng. Renal retransplantation in 41 cases [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(7): 722-725.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd